Open AccessActivity of Cefiderocol and Comparators against Isolates from Cancer Patients
Author(s) -
Kenneth V. I. Rolston,
Baghat Gerges,
Samuel A. Shelburne,
Samuel L Aitken,
Issam Raad,
Randall A. Prince
Publication year - 2020
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.01955-19
Subject(s) - stenotrophomonas maltophilia , ceftazidime/avibactam , enterobacteriaceae , microbiology and biotechnology , ceftazidime , pseudomonas aeruginosa , meropenem , amikacin , biology , bacilli , serratia , stenotrophomonas , acinetobacter , carbapenem , antimicrobial , antibiotics , pseudomonas , bacteria , antibiotic resistance , escherichia coli , gene , genetics
Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae , carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa , Stenotrophomonas maltophilia , and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.